Genocea Biosciences, Inc. (GNCA): Price and Financial Metrics

Genocea Biosciences, Inc. (GNCA): $0.23

0.06 (+33.85%)

POWR Rating

Component Grades













Add GNCA to Watchlist
Sign Up

Industry: Biotech



in industry

GNCA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for GNCA is 0.06 -- better than merely 10.13% of US stocks.
  • Of note is the ratio of Genocea Biosciences Inc's sales and general administrative expense to its total operating expenses; merely 12.28% of US stocks have a lower such ratio.
  • GNCA's price/sales ratio is 45.81; that's higher than the P/S ratio of 95.93% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Genocea Biosciences Inc, a group of peers worth examining would be VTGN, VBLT, STTK, TMDI, and GERN.
  • GNCA's SEC filings can be seen here. And to visit Genocea Biosciences Inc's official web site, go to

GNCA Valuation Summary

  • In comparison to the median Healthcare stock, GNCA's price/sales ratio is 1850.66% higher, now standing at 221.4.
  • Over the past 92 months, GNCA's EV/EBIT ratio has gone up 7.2.
  • Over the past 92 months, GNCA's EV/EBIT ratio has gone up 7.2.

Below are key valuation metrics over time for GNCA.

Stock Date P/S P/B P/E EV/EBIT
GNCA 2021-08-31 221.4 24.7 -2.8 -1.7
GNCA 2021-08-30 219.0 24.5 -2.8 -1.7
GNCA 2021-08-27 224.1 25.0 -2.8 -1.7
GNCA 2021-08-26 230.2 25.7 -2.9 -1.8
GNCA 2021-08-25 232.9 26.0 -2.9 -1.8
GNCA 2021-08-24 235.3 26.3 -3.0 -1.9

GNCA Growth Metrics

    Its 4 year price growth rate is now at -92.23%.
  • Its 2 year net cashflow from operations growth rate is now at 10.51%.
  • Its 4 year cash and equivalents growth rate is now at -28.67%.
GNCA's revenue has moved up $1,641,000 over the prior 34 months.

The table below shows GNCA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.641 -45.37 -33.196
2021-09-30 1.641 -43.907 -34.901
2021-06-30 0.453 -40.844 -35.834
2021-03-31 1.359 -40.248 -42.844
2020-12-31 1.359 -41.651 -43.714
2020-09-30 1.359 -40.995 -38.085

GNCA Price Target

For more insight on analysts targets of GNCA, see our GNCA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.10 Average Broker Recommendation 1.2 (Strong Buy)

GNCA Stock Price Chart Interactive Chart >

Price chart for GNCA

GNCA Price/Volume Stats

Current price $0.23 52-week high $2.68
Prev. close $0.17 52-week low $0.16
Day low $0.18 Volume 19,317,600
Day high $0.35 Avg. volume 1,529,276
50-day MA $0.79 Dividend yield N/A
200-day MA $1.31 Market Cap 13.22M

Genocea Biosciences, Inc. (GNCA) Company Bio

Genocea Biosciences is a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company was founded in 2006 and is based in Cambridge, Massachusetts.

GNCA Latest News Stream

Event/Time News Detail
Loading, please wait...

GNCA Latest Social Stream

Loading social stream, please wait...

View Full GNCA Social Stream

Latest GNCA News From Around the Web

Below are the latest news stories about Genocea Biosciences Inc that investors may wish to consider to help them evaluate GNCA as an investment opportunity.

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET.

GlobeNewswire | February 10, 2022

The Petri Dish: Janssen inks two local deals, Biogen licenses new drug

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.

Yahoo | January 6, 2022

Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

GlobeNewswire | January 5, 2022

Needham Thinks Genocea Biosciences’ Stock is Going to Recover

In a report released today, Gil Blum from Needham maintained a Buy rating on Genocea Biosciences (GNCA – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $1.13, close to its 52-week low of $0.92. According to, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Genocea Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $7.25, a 470.9% upside from current levels.

Catie Powers on TipRanks | January 4, 2022

Genocea Biosciences Provides Corporate Update

Enters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, has entered into an R&D collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to explore the immunogenicity of neoantigens and t

Yahoo | January 4, 2022

Read More 'GNCA' Stories Here

GNCA Price Returns

1-mo N/A
3-mo -79.46%
6-mo -85.63%
1-year -89.50%
3-year -95.86%
5-year -99.52%
YTD -80.17%
2021 -52.07%
2020 16.91%
2019 -9.84%
2018 -75.26%
2017 -71.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8115 seconds.